InnoCare Pharma Limited (HKG:9969)

InnoCare Pharma Statistics

Total Valuation

InnoCare Pharma has a market cap or net worth of HKD 26.41 billion. The enterprise value is 20.33 billion.

Market Cap	26.41B
Enterprise Value	20.33B

Important Dates

The last earnings date was Wednesday, March 25, 2026.

Earnings Date	Mar 25, 2026
Ex-Dividend Date	n/a

Share Statistics

InnoCare Pharma has 1.70 billion shares outstanding.

Current Share Class	1.43B
Shares Outstanding	1.70B
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	19.12%
Owned by Institutions (%)	24.28%
Float	1.07B

Valuation Ratios

The trailing PE ratio is 36.94.

PE Ratio	36.94
Forward PE	n/a
PS Ratio	9.99
PB Ratio	3.06
P/TBV Ratio	3.08
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	28.43
EV / Sales	7.69
EV / EBITDA	23.50
EV / EBIT	25.72
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.77, with a Debt / Equity ratio of 0.20.

Current Ratio	5.77
Quick Ratio	5.40
Debt / Equity	0.20
Debt / EBITDA	2.01
Debt / FCF	n/a
Interest Coverage	13.12

Financial Efficiency

Return on equity (ROE) is 8.89% and return on invested capital (ROIC) is 38.95%.

Return on Equity (ROE)	8.89%
Return on Assets (ROA)	4.39%
Return on Invested Capital (ROIC)	38.95%
Return on Capital Employed (ROCE)	7.54%
Weighted Average Cost of Capital (WACC)	7.25%
Revenue Per Employee	2.25M
Profits Per Employee	607,945
Employee Count	1,176
Asset Turnover	0.23
Inventory Turnover	1.48

Taxes

In the past 12 months, InnoCare Pharma has paid 12.86 million in taxes.

Income Tax	12.86M
Effective Tax Rate	1.76%

Stock Price Statistics

The stock price has increased by +56.44% in the last 52 weeks. The beta is 0.59, so InnoCare Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.59
52-Week Price Change	+56.44%
50-Day Moving Average	12.12
200-Day Moving Average	14.68
Relative Strength Index (RSI)	61.63
Average Volume (20 Days)	6,900,732

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, InnoCare Pharma had revenue of HKD 2.64 billion and earned 714.94 million in profits.

Revenue	2.64B
Gross Profit	2.43B
Operating Income	790.63M
Pretax Income	729.71M
Net Income	714.94M
EBITDA	865.21M
EBIT	790.63M
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has 7.85 billion in cash and 1.74 billion in debt, with a net cash position of 6.11 billion or 3.60 per share.

Cash & Cash Equivalents	7.85B
Total Debt	1.74B
Net Cash	6.11B
Net Cash Per Share	3.60
Equity (Book Value)	8.62B
Book Value Per Share	n/a
Working Capital	7.42B

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Depreciation & Amortization	75.96M
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 91.95%, with operating and profit margins of 29.92% and 27.05%.

Gross Margin	91.95%
Operating Margin	29.92%
Pretax Margin	27.61%
Profit Margin	27.05%
EBITDA Margin	32.74%
EBIT Margin	29.92%
FCF Margin	n/a

Dividends & Yields

InnoCare Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	2.71%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	5